Anti-microbial/Anti-fungal Tests Market Outlook (2022 to 2032)

The global anti-microbial/anti-fungal tests market is expected to reach USD 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~USD 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.

Attributes Key Insights
Anti-microbial/Anti-fungal Tests Market Value 2021 USD 2.4 Billion
Estimated Market Size 2022 USD 2.5 Billion
Projected Market Value 2032 USD 4.5 Billion
CAGR 2022 to 2032 5.7%
Market Share of Top 5 Countries 55.0%

Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.

Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Anti-microbial/Anti-fungal Tests Market from 2012 to 2021 Vs Demand Outlook for 2022 to 2032

As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~USD 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.

Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.

As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.

The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.

Anti-microbial/Anti-fungal Tests Market

What are the Key Opportunities in the Anti-microbial/Anti-fungal Tests Kit Market?

Favorable Government Initiatives and Awareness Programs to Fuel the Growth

Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.

Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining Demand for Anti-microbial/Anti-fungal Tests?

The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.

Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.

Country-wise Insights

How will the Sales in the USA Anti-microbial/Anti-fungal Tests Market Increase?

Growing Preference for Diagnostic Tests to Boost the Sales

The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.

Will China Retain its Dominance in Anti-microbial/Anti-fungal Tests Market?

Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China

China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.

Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.

It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.

How Big is the Opportunity in Germany's Anti-microbial/Anti-fungal Tests Market?

Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection

Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.

This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Anti-microbial/Anti-fungal Tests Type is Driving the Growth?

Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond

Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.

Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.

Which is the Leading End User in Anti-microbial/Anti-fungal Tests Market?

Nearly 2 out of 5 Sales are Contributed by Hospitals

As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.

Competitive Landscape

With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.

  • In July 2022, Roche announced that Elecsys HCV Duo immunoassay is now available in countries that accept the CE Mark. Elecsys HCV Duo is the only immunoassay on the market that can determine hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
  • In June 2022, Meridian Bioscience, Inc., a global leader in diagnostic testing solutions and life science raw materials, introduced two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These novel master mixes increase the molecular detection of DNA and RNA from crude faecal materials while allowing diagnostic procedures to be room temperature stabilised.

Report Scope as per Anti-microbial/Anti-fungal Tests Industry Analysis

Attribute Details
Estimated Market Size 2022 USD 2.5 Billion
Projected Market Value 2032 USD 4.5 Billion
CAGR 2022 to 2032 5.7%
Forecast Period 2012 to 2021
Historical Data Available for 2022 to 2032
Market Analysis USD Million for Value
Key Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa
Key Market Segments Covered Tests, Infection, End User, and Region
Key Companies Profiled Abbott Laboratories; bioMérieux SA; Bio-Rad Laboratories Inc; Bruker Corporation; Danaher Corporation; Erba Mannheim; F. Hoffmann-La Roche AG; Luminex Corporation; Meridian Bioscience Inc; Norgen Biotek Corp; Omega Diagnostics Group Plc; Qiagen N.V; Quidel Corporation; Thermo Fisher Scientific Inc

Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research

By Tests Type:

  • Molecular Based Tests
    • PCR Test
    • DNA Microarray
  • Phenotypic Resistance Tests
  • Complex Test Panels
  • Mass Spectrometry
  • Rapid Diagnostic Tests
    • E-Test Antibiotic/Antifungal Strips
    • Biosensor Platforms

By Infection Type:

  • Antimicrobial Resistance
    • Methicillin-Resistant Staphylococcus Aureus
    • Vancomycin-Resistant Enterococcus
    • Multi-Drug-Resistant Mycobacterium tuberculosis
    • Carbapenem-Resistant Enterobacteriaceae gut bacteria
  • Microbial Infection
  • Antifungal Resistance
    • Candida infections
    • Aspergillus infection
    • Fusariosis
    • Others
  • Fungal Infection

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Community Health Centers
  • Reference Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How much was the anti-microbial/anti-fungal tests market worth in 2021?

The global anti-microbial/anti-fungal tests market is worth USD 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.

What is the sales forecast for the anti-microbial/anti-fungal tests market through 2032?

The anti-microbial/anti-fungal tests market is expected to reach USD 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.

What are the key trends shaping the anti-microbial/anti-fungal tests market?

The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.

Which are the top five countries driving demand for anti-microbial/anti-fungal tests?

USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.

What is the North American market outlook for anti-microbial/anti-fungal tests?

North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in Europe?

Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in MEA?

Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.

Which countries are the key producers of anti-microbial/anti-fungal tests?

China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.

Who are the key players in the anti-microbial/anti-fungal tests market sphere?

Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.

Table of Content
  • 1. Executive Summary
  • 2. Market Overview
  • 3. Key Market Trends
  • 4. Key Success Factors
  • 5. Market Background
  • 6. Global Market Demand (in Value or Size in USD Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
  • 7. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type
    • 7.1. Molecular-Based Tests
      • 7.1.1. PCR Test
      • 7.1.2. DNA Microarray
    • 7.2. Phenotypic Resistance Tests
    • 7.3. Complex Test Panels
    • 7.4. Mass Spectrometry
    • 7.5. Rapid Diagnostic Tests
      • 7.5.1. E-Test Antibiotic/Antifungal Strips
      • 7.5.2. Biosensor Platforms
  • 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type
    • 8.1. Antimicrobial Resistance
      • 8.1.1. Methicillin-Resistant Staphylococcus Aureus
      • 8.1.2. Vancomycin-Resistant Enterococcus
      • 8.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis
      • 8.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria
    • 8.2. Microbial Infection
    • 8.3. Antifungal Resistance
      • 8.3.1. Candida infections
      • 8.3.2. Aspergillus infection
      • 8.3.3. Fusariosis
      • 8.3.4. Others
    • 8.4. Fungal Infection
  • 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
    • 9.1. Hospitals
    • 9.2. Ambulatory Surgical Centers
    • 9.3. Clinics
    • 9.4. Community Health Centers
    • 9.5. Reference Laboratories
  • 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
    • 10.1. North America
    • 10.2. Latin America
    • 10.3. Europe
    • 10.4. East Asia
    • 10.5. South Asia
    • 10.6. Oceania
    • 10.7. Middle East and Africa (MEA)
  • 11. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 12. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 13. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 14. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 15. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 16. Oceania Market 2017 to 2021 and Forecast 2022 to 2032
  • 17. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
  • 18. Market Structure Analysis
  • 19. Competition Analysis
    • 19.1. Abbott Laboratories
    • 19.2. bioMérieux SA
    • 19.3. Bio-Rad Laboratories Inc.
    • 19.4. Bruker Corporation
    • 19.5. Danaher Corporation
    • 19.6. Erba Mannheim
    • 19.7. F. Hoffmann-La Roche AG
    • 19.8. Luminex Corporation
    • 19.9. Meridian Bioscience Inc.
    • 19.10. Norgen Biotek Corp.
    • 19.11. Omega Diagnostics Group Plc.
    • 19.12. Qiagen N.V.
    • 19.13. Quidel Corporation
    • 19.14. Thermo Fisher Scientific Inc.
  • 20. Assumptions and Acronyms Used
  • 21. Research Methodology
Recommendations

Healthcare

Fertility and Pregnancy Rapid Test Kit Market

October 2023

REP-GB-607

183 pages

Healthcare

Fungal Keratitis Treatment Market

August 2023

REP-GB-6934

249 pages

Healthcare

Fungal Testing Kits Market

March 2023

REP-GB-12418

342 pages

Healthcare

At-Home Vaginal pH Test Kit Market

June 2022

REP-GB-8318

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Anti-microbial/Anti-fungal Tests Market

Schedule a Call